Dianthus Therapeutics (DNTH) Change in Acquisitions & Divestments (2019 - 2025)

Dianthus Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $78.6 million for Q3 2025.

• On a quarterly basis, Change in Acquisitions & Divestments rose 313.53% year-over-year to $78.6 million in Q3 2025; TTM through Sep 2025 was $305.3 million, a 408.86% increase from a year earlier, with the FY2024 full-year figure at $127.0 million, up 63.27% from the prior year.
• Change in Acquisitions & Divestments grew to $78.6 million in Q3 2025 per DNTH's latest filing, from $59.6 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $85.0 million in Q4 2024 and bottomed at $2.0 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $20.4 million (2023), against an average of $32.3 million.
• Across the five-year window, Change in Acquisitions & Divestments plunged 94.29% in 2022 and jumped 800.0% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $35.0 million in 2021, then plunged by 94.29% to $2.0 million in 2022, then soared by 800.0% to $18.0 million in 2023, then surged by 372.22% to $85.0 million in 2024, then retreated by 7.56% to $78.6 million in 2025.
• Per Business Quant, the three latest DNTH Change in Acquisitions & Divestments figures stand at $78.6 million (Q3 2025), $59.6 million (Q2 2025), and $82.1 million (Q1 2025).